Ribociclib (LuciRibo) 200mg*21's | Lucius Laos Generic | GLT

Generic Information: LuciRibo (Laos)

LuciRibo is a Laos-market brand of ribociclib manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd., a Lao pharmaceutical company focused on oncology medicines. Each pack contains 21 film-coated tablets of 200 mg. LuciRibo offers patients a lower-cost alternative to the Novartis originator Kisqali for HR-positive, HER2-negative breast cancer.

What Is Ribociclib (LuciRibo) Used For?

LuciRibo is used to treat HR-positive, HER2-negative breast cancer. In advanced or metastatic disease it is given in combination with an aromatase inhibitor or fulvestrant, and it is also used as adjuvant treatment for HR-positive, HER2-negative early breast cancer at high risk of recurrence. Like all ribociclib products, LuciRibo is always used together with endocrine therapy, not as a standalone treatment.

How Does Ribociclib Work?

Ribociclib blocks cyclin-dependent kinases 4 and 6, the enzymes that control the G1-to-S checkpoint of the cell cycle. HR-positive breast-cancer cells depend on CDK4/6 signalling to keep dividing, so inhibiting these kinases arrests them at the checkpoint and slows tumour growth. Combined with hormone therapy that suppresses oestrogen-driven growth signals, ribociclib attacks the cancer from two angles at once.

Indications

The approved indications are HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, and HR-positive, HER2-negative stage II/III early breast cancer at high risk of recurrence as adjuvant therapy. An oncologist should initiate and supervise treatment, and hormone-receptor and HER2 status must be confirmed before starting.

Dosage

The standard dose for advanced or metastatic disease is 600 mg, taken as three 200 mg tablets once daily with or without food, in 28-day cycles of 21 days on and 7 days off. A 21-tablet pack covers one week of active dosing. For early breast cancer the dose is 400 mg daily. The dose may be reduced to 400 mg or 200 mg daily to manage neutropenia, liver-enzyme rises or QT prolongation.

Side Effects

Common side effects include neutropenia, nausea, fatigue, diarrhoea, vomiting, hair loss, headache and constipation. More serious adverse events can include QT-interval prolongation, liver toxicity, interstitial lung disease and severe skin reactions. Blood counts, liver function, electrolytes and the ECG are monitored regularly, and patients should report fever, persistent diarrhoea, yellowing of the skin or new breathing difficulty promptly.

Storage

Store LuciRibo tablets at room temperature in the original container, protected from moisture, and out of the reach of children. Do not use past the expiry date shown on the pack.

Why Choose LuciRibo Through GLT?

LuciRibo provides overseas patients and institutions with a lower-cost ribociclib sourced from the Lao market, where manufacturing keeps pricing accessible. GLT verifies product authenticity and ships worldwide from a Hong Kong-licensed facility, giving patients a dependable and affordable supply for longer-term breast-cancer treatment.

How to Order

To order LuciRibo (ribociclib) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We will confirm current availability, pricing and delivery to your country, and we ship from a Hong Kong-licensed facility.

FAQ

Is LuciRibo the same as Kisqali? Yes — LuciRibo contains the same ribociclib molecule, manufactured by Lucius Pharmaceuticals in Laos.

What is the dosing schedule? 600 mg once daily for 21 days, then a 7-day break, repeated every 28 days.

Do I need a prescription? Yes, ribociclib is a prescription-only oncology medicine and requires a valid prescription.